Table 1.
Receptor type | Affinity (Ki) | Typology | Biological action vs agonist | Experimental system | Cells/tissues expressing target receptors | References |
---|---|---|---|---|---|---|
Dopamine | ||||||
D1 | − | Rat | CHO cells | Lawler et al. [45] | ||
− | Human | Shapiro et al. [36] | ||||
D2 | ++ | Rat | Rat striatum | Lawler et al. [45] | ||
+++ | Rat (D2S) | Antagonism | Inhibition of forskolin-induced cAMP production | CHO | ||
+++ | Rat (D2L) | CHO | ||||
++ | Rat (D2L) | Partial agonism | Isoproterenol stimulation of cAMP accumulation | C6 glioma | ||
+++ | Human | Antagonism | Quinpirole-induced GTPase activity | Rat brain striatal membranes | Inoue et al. [130] | |
Partial agonism | Inhibition of forskolin-induced cAMP production | CHO | Burris et al. [37] | |||
Antagonism | Modulation of GIRK currents | MES-23.5 | Shapiro et al. [36] | |||
Antagonism | GTPγS binding | CHO | ||||
Partial agonism | Inhibition of forskolin-induced prolactin release | GFH4C1 | Aihara et al. [208] | |||
Inhibition of forskolin-induced cAMP production | ||||||
Partial agonism | Inhibition of forskolin-induced cAMP production | CHO | Tadori et al. [209] | |||
Partial agonism | Inhibition of dopamine-induced ERK phosphorylation | CHO | Bruins Slot et al. [210] | |||
Partial agonism | D2-mediated MAPK phosphorylation |
CHO | Urban et al. [42] | |||
D2-mediated potentiation of acid arachidonic release | ||||||
Agonism | Inhibition of forskolin-induced cAMP production | CHO (low-density hD2SRs) | Tadori et al. [40] | |||
Partial agonism | CHO (high-density hD2SRs) | |||||
Antagonism | CHO (low-density hD2LRs) | |||||
Partial agonism | CHO (high-density hD2LRs) | |||||
D3 | ++ | Rat | Lawler et al. [45] | |||
++ | Rat | C6 glioma | ||||
++ | Human | Partial agonism | Inhibition of forskolin-induced cAMP production | CHO | Tadori et al. [211] | |
Partial agonism | Inhibition of forskolin-induced cAMP production | CHO | Tadori et al. [40] | |||
D4 | +/− | Rat | CHO | Lawler et al. [45] | ||
+/− | Rat | Partial agonism | Modulation of GIRK currents | Xenopus laevis oocytes | Newmann-Tancredi et al. [212] | |
D5 | − | Rat | CHO | Lawler et al. [45] | ||
− | Human | Shapiro et al. [36] | ||||
DAT | − | Human | ||||
Serotonin | ||||||
5-HT1A | ++ | Human | Partial agonism | Inhibition of forskolin-induced cAMP production | CHO | Shapiro et al. [36] |
Partial agonism | GTPγS binding | CHO | Jordan et al. [56] | |||
Partial agonism | GTPγS binding | Rat hippocampal membranes | Stark et al. [57] | |||
Agonism | Firing rate | 5-HT dorsal raphe nuclei | Stark et al. [57] | |||
5-HT1B | +/− | Human | Shapiro et al. [36] | |||
5-HT1D | + | Human | Shapiro et al. [36] | |||
5-HT1E | − | Human | Shapiro et al. [36] | |||
5-HT2A | ++ | Human | Partial agonism | Stimulation of PI hydrolysis | C6-glioma cells expressing endogenous 5-HT2ARs | Shapiro et al. [36] |
GF62 | ||||||
5-HT2B | +++ | Human | Inverse agonism | Stimulation of PI hydrolysis | HEK-293 | Shapiro et al. [36] |
5-HT2C | + | Human | Partial agonism | Stimulation of PI hydrolysis | PO1C | Shapiro et al. [36] |
Agonism | Stimulation of PI hydrolysis | COS-7 | ||||
5-HT3 | +/− | Rat | Shapiro et al. [36] | |||
5-HT5A | − | Human | Shapiro et al. [36] | |||
5-HT6 | +/− | Rat | HEK-293 | Lawler et al. [45] | ||
+/− | Human | Antagonism | Stimulation of cAMP production | HEK-293 | Shapiro et al. [36] | |
5-HT7 | + | Rat | HEK-293 | Lawler et al. [45] | ||
++ | Human | Partial agonism | Stimulation of cAMP production | HEK-293 | Shapiro et al. [36] | |
SERT | − | Human | Shapiro et al. [36] | |||
Noradrenaline | ||||||
α1A | + | Human | Antagonism | Shapiro et al. [36] | ||
α1B | + | Human | Antagonism | |||
α2A | + | Human | Antagonism | |||
α2B | +/− | Human | ||||
α2C | + | Human | Antagonism | |||
β1 | +/− | Human | ||||
β2 | +/− | Human | ||||
NET | − | Human | ||||
Histamine | ||||||
H1 | + | Human | Antagonism | Shapiro et al. [36] | ||
H2 | − | Human | ||||
H3 | +/− | Guinea pig | ||||
H4 | − | Human | ||||
Acetylcholine | ||||||
M1 | − | Human | Shapiro et al. [36] | |||
M2 | − | Human | ||||
M3 | − | Human | ||||
M4 | − | Human | ||||
M5 | − | Human | ||||
GABA | ||||||
GABA-A | − | Rat | Shapiro et al. [36] | |||
GABA-B | − | Rat | ||||
Glutamate | ||||||
NMDA | − | Rat | Shapiro et al. [36] | |||
Opiate | ||||||
κ | − | Human | Shapiro et al. [36] | |||
µ | − | Human | ||||
δ | − | Human |
Where available, the results of functional studies to evaluate aripiprazole intrinsic activity on target receptors compared with the agonist are reported
cAMP cyclic adenosine monophosphate, CHO Chinese hamster ovaries, GIRK G-protein-coupled inward rectifier K+, GTP gamma-triphosphate, hD2LR human D2 long receptor, hD2SR human D2 short receptor, HEK human embryonic kidney, MAPK mitogen-activated protein kinase, +++ indicates ≤1—very high affinity, ++ indicates ≤10—high affinity, + indicates ≤100—moderate affinity, +/− indicates ≤1000—limited affinity, − indicates >1000—negligible affinity